share_log

ICU Medical's (NASDAQ:ICUI) Investors Will Be Pleased With Their Solid 107% Return Over the Last Year

ICU Medical's (NASDAQ:ICUI) Investors Will Be Pleased With Their Solid 107% Return Over the Last Year

icu醫療(納斯達克:ICUI)的投資者將會對他們在過去一年內穩固的107%回報感到滿意
Simply Wall St ·  11/07 20:32

When you buy shares in a company, there is always a risk that the price drops to zero. But if you pick the right business to buy shares in, you can make more than you can lose. For example, the ICU Medical, Inc. (NASDAQ:ICUI) share price had more than doubled in just one year - up 107%. On top of that, the share price is up 18% in about a quarter. But this move may well have been assisted by the reasonably buoyant market (up 12% in 90 days). In contrast, the longer term returns are negative, since the share price is 25% lower than it was three years ago.

當您購買一家公司的股票時,總會存在價格降至零的風險。但如果您選擇了正確的業務購買股票,您可以獲得比您可能損失的更多。例如,icu醫療公司(納斯達克:ICUI)的股價在短短一年內翻了一番多 - 漲了107%。除此之外,股價在大約一個季度內上漲了18%。但這一舉動很可能受到了相對樂觀的市場的支撐(90天內上漲了12%)。相比之下,從長期來看回報是負面的,因爲股價比三年前低了25%。

So let's investigate and see if the longer term performance of the company has been in line with the underlying business' progress.

那麼,讓我們調查一下並查看公司的長期表現是否符合基本業務的進展。

ICU Medical isn't currently profitable, so most analysts would look to revenue growth to get an idea of how fast the underlying business is growing. Shareholders of unprofitable companies usually desire strong revenue growth. That's because fast revenue growth can be easily extrapolated to forecast profits, often of considerable size.

icu醫療目前並不盈利,因此大多數分析師傾向於查看營業收入增長來了解基礎業務增長的速度。通常,虧損公司的股東希望看到強勁的營業收入增長。這是因爲快速的營業收入增長往往可以輕鬆推斷出盈利,通常規模可觀。

In the last year ICU Medical saw its revenue grow by 0.5%. That's not great considering the company is losing money. In contrast, the share price took off during the year, gaining 107%. We're happy that investors have made money, though we wonder if the increase will be sustained. It's quite likely that the market is considering other factors, not just revenue growth.

在過去一年,icu醫療的營業收入增長了0.5%。考慮到公司虧損,這並不理想。相比之下,股價在該年份大幅上升,漲幅達到了107%。我們很高興投資者賺到了錢,儘管我們在想這種增長是否能持續。市場很可能正在考慮其他因素,而不僅僅是營業收入增長。

You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).

您可以在下方圖片中看到盈利和營業收入隨時間的變化(單擊圖表查看準確數值)。

big
NasdaqGS:ICUI Earnings and Revenue Growth November 7th 2024
納斯達克:ICUI 2024年11月7日的盈利和營業收入增長

You can see how its balance sheet has strengthened (or weakened) over time in this free interactive graphic.

你可以在這個免費的互動圖表中看到它的資產負債表如何隨着時間的推移而加強(或削弱)。

A Different Perspective

另一種看法

We're pleased to report that ICU Medical shareholders have received a total shareholder return of 107% over one year. Since the one-year TSR is better than the five-year TSR (the latter coming in at 0.4% per year), it would seem that the stock's performance has improved in recent times. Given the share price momentum remains strong, it might be worth taking a closer look at the stock, lest you miss an opportunity. While it is well worth considering the different impacts that market conditions can have on the share price, there are other factors that are even more important. Like risks, for instance. Every company has them, and we've spotted 2 warning signs for ICU Medical (of which 1 doesn't sit too well with us!) you should know about.

我們很高興地報告,icu醫療的股東在一年內獲得了總股東回報率爲107%。 由於一年的TSR優於五年的TSR(後者爲每年0.4%),似乎股票的表現在最近有所改善。 鑑於股價動能仍然強勁,值得更仔細地研究這支股票,以免錯失機會。 儘管考慮市場條件對股價可能產生的不同影響非常重要,但還有其他更重要的因素。 比如風險。 每家公司都有風險,我們已經發現icu醫療存在2個警示信號(其中1個信號不太令我們滿意!)您應該知道。

If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: many of them are unnoticed AND have attractive valuation).

如果您喜歡與管理層一起購買股票,那麼您可能會喜歡這個公司的免費列表。 (提示:其中許多公司不爲人注意且具有吸引力的估值。)

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on American exchanges.

請注意,本文所引述的市場回報反映了目前在美國交易所上市的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂嗎?請直接與我們聯繫。或者,發送電子郵件至editorial-team @ simplywallst.com。
Simply Wall St的這篇文章是一般性質的。我們僅基於歷史數據和分析師預測提供評論,使用公正的方法,我們的文章並非意在提供財務建議。這並不構成買入或賣出任何股票的建議,並且不考慮您的目標或財務狀況。我們旨在爲您帶來基於基礎數據驅動的長期聚焦分析。請注意,我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St對提及的任何股票都沒有持倉。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論